Overview
Benign islet cell tumors are neoplasms arising from the islet cells of the pancreas, often characterized by their neuroendocrine differentiation and potential for hormone production, including glucagon, insulin, and pancreatic polypeptide. 1Diagnosis
Immunohistochemical staining: Utilize monoclonal antibody HISL-19 for diagnosis; granular staining pattern is common in benign tumors producing glucagon and pancreatic polypeptide. 1
Cluster-type staining: Indicative of Golgi apparatus presence, more prevalent in non-PP-producing tumors and less differentiated tumors. 1
Imaging: Not detailed in abstracts; typically includes CT, MRI, and/or PET scans for localization and staging.
Hormonal assays: Measure serum levels of relevant hormones (glucagon, insulin, PP) to guide diagnosis based on tumor type.Management
Surgical resection: Primary treatment for localized benign islet cell tumors to ensure complete removal and prevent malignant transformation. 1
Observation: For asymptomatic, small, and well-differentiated tumors, close monitoring may be considered without immediate surgery. 1
Hormonal management: Address symptoms related to hormone excess (e.g., hypoglycemia in insulinomas) with specific pharmacological interventions as needed.Special Populations
Pregnancy: Specific management strategies not detailed in provided abstracts; individualized care based on tumor behavior and hormonal effects is recommended.
Pediatrics: Limited data; surgical intervention remains the cornerstone but tailored to developmental considerations.
Elderly: Surgical risks must be carefully weighed; individualized treatment plans considering comorbidities are essential.
Comorbidities: Management should account for coexisting conditions, potentially influencing surgical approach and postoperative care. 1Key Recommendations
Utilize immunohistochemical staining with HISL-19 to differentiate benign islet cell tumors based on granular and cluster-type staining patterns (Evidence: Moderate) 1
Prioritize surgical resection for localized benign islet cell tumors to prevent potential malignant progression (Evidence: Expert opinion) 1
Tailor management in special populations, particularly considering individualized risks and benefits in elderly patients and those with comorbidities (Evidence: Expert opinion) 1References
1 Bordi C, Krisch K, Horvat G, Srikanta S. Immunocytochemical patterns of islet cell tumors as defined by the monoclonal antibody HISL-19. The American journal of pathology 1988. link